Positive Results for Relvar® Ellipta® Lung Function Study in Patients with Well-Controlled Asthma

Respiratory February 23, 2017 at 3:19 PM 0 comments

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from a non-inferiority lung function study, which demonstrated that patients with well-controlled asthma were able to switch to the once-daily Relvar® Ellipta® (fluticasone furoate/vilanterol, FF/VI) 100/25, an inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) combination, from the twice-dailyRead More

Philips Reinforces Leadership in Image-Guided Therapy Solutions with Global Launch of next Generation Azurion Platform

Philips Reinforces Leadership in Image-Guided Therapy Solutions with Global Launch of next Generation Azurion Platform

Uncategorized February 23, 2017 at 3:03 PM 0 comments

Developed in collaboration with leading hospitals worldwide, Philips Azurion is an innovative image-guided therapy platform that allows clinicians to easily and confidently perform a wide range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care Azurion is powered by ConnectOS, Philips’ newly developed operating system toRead More

Janssen Presents Newly-Published Data on the Use of ZYTIGA® (Abiraterone Acetate) Plus Prednisone in the Real-World, Outside the Clinical Trial Setting

Urology February 17, 2017 at 2:56 PM 0 comments

Janssen Presents Newly-Published Data on the Use of ZYTIGA® (Abiraterone Acetate) Plus Prednisone in the Real-World, Outside the Clinical Trial Setting1 Beerse, Belgium, February 17, 2017 – Janssen-Cilag International NV today announced the publication of data revealing radiographic progression-free survival (rPFS) of 16.5 months (95% CI, 13.5–20.0) and treatment durationRead More

New Data Shows Stelara® (Ustekinumab) Maintained Clinical Response and Remission After Two Years of Treatment in Patients with Moderate to Severe Crohn’s Disease

Gastroenterology February 17, 2017 at 2:22 PM 0 comments

Results of the IM-UNITI Study Presented at the 12th Congress of ECCO Barcelona, Spain, February 17, 2017 – Janssen-Cilag International NV (“Janssen”) announced today new two-year data from the ongoing IM-UNITI long-term extension (LTE) study evaluating the efficacy and safety of subcutaneous (SC) STELARA® (ustekinumab) in patients with moderate toRead More

Polyganics’ “STOP NEUROMA” Study Interim Data Shows Reduction in Pain

Uncategorized February 16, 2017 at 10:20 AM 0 comments

NEUROCAP® 3-month interim data show an average pain reduction of 84% Final patient recruited in “STOP NEUROMA” clinical study, full data due to be reported by Q3 2018. Groningen, The Netherlands, February 16, 2017 – Polyganics, a privately held medical technology company, announced today that interim results show a sharp improvementRead More

BIAL and Neurocrine Announce Exclusive North American Licensing Agreement for Opicapone

Uncategorized February 10, 2017 at 2:28 PM 0 comments

ONGENTYS®(opicapone) Approved in Europe in June 2016 Porto, Portugal and San Diego, California, February 10, 2017 – BIAL and Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North America. ONGENTYS® (opicapone) is a once-daily,Read More

Juntendo University Research: Brain Imaging and Causal Assessment of Impairments Reveals Metamemory Regions

Juntendo University Research: Brain Imaging and Causal Assessment of Impairments Reveals Metamemory Regions

Neurology January 18, 2017 at 2:43 PM 0 comments

Tokyo, January 18, 2017 – Juntendo University researchers identify areas of the brain responsible for metacognitive memory evaluation in macaque monkeys. “We know how confidently we know,” explains Yasushi Miyashita and colleagues at Juntendo University Graduate School of Medicine and the University of Tokyo School of Medicine in their recent report.Read More

AMRA Announces $9 Million Investment from Pfizer Venture Investments, Novo Seeds and Industrifonden

Uncategorized January 17, 2017 at 4:24 PM 0 comments

AMRA is the leader in setting the new standard for advanced body composition measurement Investment supports AMRA’s goal to redefine obesity and support clinical trials Sweden, January 17, 2017 – Swedish-based digital health company AMRA has announced today a $9 million funding round co-led by US-based Pfizer Venture Investments and leadingRead More

Introducing EMJ Innovations 1.1

Introducing EMJ Innovations 1.1

Innovations January 10, 2017 at 9:01 AM 0 comments

United Kingdom, January 10, 2017: Happy new year and welcome to our first journal of the year, the inaugural edition of the European Medical Journal Innovations eJournal, our new venture aimed at presenting recent developments in medical modernisation and eagerly anticipated technological advances of the near future. With highlights fromRead More

RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT® for Migraines with Pharmatronic Co. In South Korea

Oncology December 19, 2016 at 9:41 AM 0 comments

RedHill and its co-development partner, IntelGenxCorp. (IntelGenx), have signed a definitive agreement with Pharmatronic Co., granting an exclusive license to commercialize the acute migraine drug RIZAPORT® in South Korea This agreement follows the previously announced commercialization agreement with Grupo JUSTE S.A.Q.F for Spain, and the subsequent submission of a nationalRead More